铁死亡 (Ferroptosis) 是一种非凋亡形式的受控细胞死亡。它不同于其他受控细胞死亡表型,例如凋亡和坏死性凋亡。铁死亡的特征是广泛的脂质过氧化,可以通过铁螯合剂或亲脂性抗氧化剂抑制。从机制上讲,铁死亡诱导剂分为两类:(1) 通过 xc− 系统抑制胱氨酸输入的抑制剂(例如 Erastin),随后导致谷胱甘肽 (GSH) 消耗;(2) 谷胱甘肽过氧化物酶 4 (GPX4) 的共价抑制剂(例如 (1S, 3R)-RSL3)。由于 GPX4 使用 GSH 作为共底物来还原脂质氢过氧化物,因此这两类化合物最终都会导致 GPX4 活性丧失,随后脂质活性氧 (ROS) 水平升高,从而导致细胞死亡。
铁死亡是一种依赖铁和 ROS 的受控细胞死亡 (RCD)。失调的铁死亡与多种生理和病理过程有关,包括癌细胞死亡、神经毒性、神经退行性疾病、急性肾衰竭、药物引起的肝毒性、肝脏和心脏缺血/再灌注损伤以及 T 细胞免疫。
Ferroptosis is a non-apoptotic form of regulated cell death. It is distinct from other regulated cell death phenotypes, such as apoptosis and necroptosis. Ferroptosis is characterized by extensive lipid peroxidation, which can be suppressed by iron chelators or lipophilic antioxidants. Mechanistically, Ferroptosis inducers are divided into two classes: (1) inhibitors of cystine import via system xc− (e.g., Erastin), which subsequently causes depletion of glutathione (GSH), and (2) covalent inhibitors (e.g., (1S, 3R)-RSL3) of glutathione peroxidase 4 (GPX4). Since GPX4 reduces lipid hydroperoxides using GSH as a co-substrate, both compound classes ultimately result in loss of GPX4 activity, followed by elevated levels of lipid reactive oxygen species (ROS) and consequent cell death.
Ferroptosis is an iron- and ROS-dependent form of regulated cell death (RCD). Misregulated Ferroptosis has been implicated in multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity.
SZ0232 是一种选择性 mPGES-2 抑制剂,它通过氢键和 π-π 堆叠结合至 mPGES-2 活性位点,减少前列腺素 E2 (PGE2) 生成并阻断 PGE2-EP3 通路,同时通过激活血红素依赖的 p53/SLC7A11/GPX4 轴调控铁死亡 (Ferroptosis)、抑制脂质过氧化并保护肾小管,还可增强葡萄糖刺激的胰岛素分泌、抑制 β 细胞衰老、改善葡萄糖稳态,减少糖尿病小鼠的肾脏脂质蓄积、减轻纤维化并改善肾功能障碍,在多囊肾病模型中抑制肾囊肿生长,其促胰岛素分泌效应随动物年龄增长而增强,可用于 2 型糖尿病、急性肾损伤、糖尿病肾病及常染色体显性多囊肾病的相关研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号